ketamine has been researched along with Chronic Disease in 121 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term S(+)-ketamine treatment is effective in causing pain relief in CRPS-1 patients with analgesia outlasting the treatment period by 50 days." | 9.15 | Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. ( Aarts, L; Bauer, M; Dahan, A; Niesters, M; Noppers, I; Olofsen, E; Sarton, E; Sigtermans, M, 2011) |
| "We examined the role of N-methyl-D-aspartate (NMDA) receptors in chronic (pathological) pain in humans by using the NMDA receptor antagonist ketamine as a probe." | 9.09 | Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. ( Oye, I; Rabben, T; Skjelbred, P, 1999) |
| "The analgesic effect of the N-methyl-D-aspartate (NMDA) receptor blocker ketamine in 17 patients (13 females and four males, age 32-88 years) who had suffered neuropathic orofacial pain for time periods ranging from 6 months to 28 years was examined." | 9.09 | Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. ( Rabben, T; Øye, I, 2001) |
| "Ten patients (4 female, 6 male) aged 34-67 years suffering from peripheral neuropathic pain participated in a double-blind placebo-controlled study where ketamine or magnesium chloride were administered by a 10 min bolus infusion (ketamine: 0." | 9.08 | NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. ( Arendt-Nielsen, L; Felsby, S; Jensen, TS; Nielsen, J, 1996) |
| "While most studies on intravenous ketamine show acute analgesic effects, three recent trials on long-term ketamine treatment (days to weeks) demonstrate the effectiveness of ketamine in causing long-term (months) relief of chronic pain." | 8.86 | Ketamine for the treatment of chronic non-cancer pain. ( Aarts, L; Dahan, A; Niesters, M; Noppers, I; Sarton, E; Smith, T, 2010) |
| "Ketamine has diverse effects that may be of relevance to chronic pain including: N-methyl-D-aspartic acid, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate, gamma-aminobutyric acid(A) receptors; inhibition of voltage gated Na(+) and K(+) channels and serotonin, dopamine re-uptake." | 8.82 | Ketamine in chronic pain management: an evidence-based review. ( Cousins, MJ; Hocking, G, 2003) |
| "Rapid anti-suicidal and antidepressant effects of ketamine have repeatedly been confirmed in unipolar and bipolar depression." | 7.88 | Rapid antidepressant effect of S-ketamine in schizophrenia. ( Bartova, L; Dold, M; Kasper, S; Milenkovic, I; Papageorgiou, K; Weidenauer, A; Willeit, M; Winkler, D, 2018) |
| "We report a case series on the observed effects of low-dose ketamine infusions in 4 critically ill patients with varying complications related to prolonged critical illness." | 7.83 | Low-Dose Ketamine in Chronic Critical Illness. ( Darrah, D; Moitra, A; Moitra, VK; Patel, MK; Wunsch, H, 2016) |
| "The aim of the study was to explore the analgesic effect of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine in acute experimental versus chronic spontaneous pain in Complex Regional Pain Syndrome type 1 (CRPS-1) patients." | 7.76 | An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. ( Bauer, M; Dahan, A; Mooren, R; Noppers, I; Olofsen, E; Sarton, E; Sigtermans, M, 2010) |
| "To determine the sensitivity to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia." | 7.74 | Determination of sensitivity of male Wistar rats to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia in comparison with control group. ( Amini, B; Heydarpour, F; Heydarpour, P; Kalantari, S; Rostami, A, 2007) |
| "This prospective audit was undertaken in order to document the analgesic response and adverse effects of concurrent short-term ('burst') triple-agent analgesic (ketamine, an opioid and an anti-inflammatory agent--either steroidal or non-steroidal) administration, for episodes of acute on chronic pain." | 7.73 | Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic pain. ( Ashby, M; Good, P; Goodchild, C; Jackson, K; Tullio, F, 2005) |
| "We examined the analgesic effect of racemic ketamine and its 2 enantiomers in 16 female patients (age: 20-29 years) suffering acute pain after oral surgery and in 7 female patients (age: 42-79 years) suffering chronic neuropathic orofacial pain." | 7.69 | Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. ( Mathisen, LC; Skjelbred, P; Skoglund, LA; Øye, I, 1995) |
| "Ketamine is an N-methyl-d-aspartate receptor antagonist that has been shown to be useful in the reduction of acute postoperative pain and analgesic consumption in a variety of surgical interventions with variable routes of administration." | 6.75 | Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. ( Abdu, WA; Beach, ML; Brown, JR; Clark, JA; Loftus, RW; Sengupta, DK; Yeager, MP, 2010) |
| "0001) with pain relief within 10 min of dosing and lasting for up to 60 min." | 6.71 | Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. ( Albin, R; Brennen, L; Brookoff, D; Carr, DB; Denman, WT; Firestone, L; Goudas, LC; Green, G; Hamilton, D; Lavin, PT; Mermelstein, F; Rogers, MC; Staats, PS, 2004) |
| " Dose-response estimation in 2 patients with PNS-related neuropathic pain revealed that ketamine was effective in dose-related fashion." | 6.67 | Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. ( Arndt, G; Backonja, M; Check, B; Gombar, KA; Zimmermann, M, 1994) |
| "Ketamine is an N-methyl-D-aspartate receptor antagonist that has been in clinical use in the USA for over 30 years." | 6.47 | Ketamine in pain management. ( Cohen, SP; Gupta, A; Liao, W; Plunkett, A, 2011) |
| " There was no consistent dose-response relation." | 6.46 | Use of oral ketamine in chronic pain management: a review. ( Blonk, MI; Huygen, FJ; Koder, BG; van den Bemt, PM, 2010) |
| "Ketamine is a dissociative anaesthetic; its mechanism of action is primarily an antagonism of the N-methyl-D-aspartate (NMDA) receptor." | 6.43 | The role of ketamine in pain management. ( Schug, SA; Visser, E, 2006) |
| "Schizophrenia is a chronic and devastating disease with an overall lifetime risk of 1%." | 5.46 | Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. ( Hauser, MJ; Isbrandt, D; Roeper, J, 2017) |
| "Ketamine is a centrally acting agent believed to work through blockade of N-methyl-D- aspartate receptors and is being increasingly used for the treatment of refractory CRPS, although the basis for the drug's effects and efficacy at different stages of the syndrome remains unclear." | 5.42 | Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice. ( Clark, JD; Huang, TT; Kingery, WS; Leu, D; Tajerian, M; Yang, P, 2015) |
| "It had less effect on tactile allodynia (CCI)." | 5.35 | Effects of norketamine enantiomers in rodent models of persistent pain. ( Crooks, PA; Hojomat, M; Holtman, JR; Johnson-Hardy, JK; Kleven, M; Wala, EP, 2008) |
| "Glycine (GLY), which acts as an obligatory co-agonist at the NMDAR-GLY site, induces PPI deficits in rats although, consistent with the hypo-NMDAR hypothesis, improves negative and cognitive symptoms in schizophrenia patients." | 5.34 | High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. ( Bar, G; Ebstein, RP; Ermilov, M; Heresco-Levy, U; Javitt, DC; Levin, R, 2007) |
| "Neuropathic pain has been shown to respond to drugs that block the N-methyl-D-aspartate (NMDA) receptor, such as ketamine and amantidine." | 5.31 | An unusual case of chronic neuropathic pain responds to an optimum frequency of intravenous ketamine infusions. ( Mitchell, AC, 2001) |
| "Long-term S(+)-ketamine treatment is effective in causing pain relief in CRPS-1 patients with analgesia outlasting the treatment period by 50 days." | 5.15 | Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. ( Aarts, L; Bauer, M; Dahan, A; Niesters, M; Noppers, I; Olofsen, E; Sarton, E; Sigtermans, M, 2011) |
| "The analgesic effect of the N-methyl-D-aspartate (NMDA) receptor blocker ketamine in 17 patients (13 females and four males, age 32-88 years) who had suffered neuropathic orofacial pain for time periods ranging from 6 months to 28 years was examined." | 5.09 | Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. ( Rabben, T; Øye, I, 2001) |
| "Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist used recently for analgesia in patients with chronic pain." | 5.09 | Clinical experience with oral ketamine. ( Enarson, MC; Hays, H; Woodroffe, MA, 1999) |
| "We examined the role of N-methyl-D-aspartate (NMDA) receptors in chronic (pathological) pain in humans by using the NMDA receptor antagonist ketamine as a probe." | 5.09 | Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. ( Oye, I; Rabben, T; Skjelbred, P, 1999) |
| "Ten patients (4 female, 6 male) aged 34-67 years suffering from peripheral neuropathic pain participated in a double-blind placebo-controlled study where ketamine or magnesium chloride were administered by a 10 min bolus infusion (ketamine: 0." | 5.08 | NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. ( Arendt-Nielsen, L; Felsby, S; Jensen, TS; Nielsen, J, 1996) |
| "The implications of these findings are drawn out for treatment of ketamine-induced ulcerative cystitis in which interventions from urologists and from addiction specialists should be coordinated." | 4.88 | Ketamine use: a review. ( Curran, HV; Morgan, CJ, 2012) |
| "While most studies on intravenous ketamine show acute analgesic effects, three recent trials on long-term ketamine treatment (days to weeks) demonstrate the effectiveness of ketamine in causing long-term (months) relief of chronic pain." | 4.86 | Ketamine for the treatment of chronic non-cancer pain. ( Aarts, L; Dahan, A; Niesters, M; Noppers, I; Sarton, E; Smith, T, 2010) |
| "Ketamine has diverse effects that may be of relevance to chronic pain including: N-methyl-D-aspartic acid, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate, gamma-aminobutyric acid(A) receptors; inhibition of voltage gated Na(+) and K(+) channels and serotonin, dopamine re-uptake." | 4.82 | Ketamine in chronic pain management: an evidence-based review. ( Cousins, MJ; Hocking, G, 2003) |
| " Sublingual ketamine has been shown to be efficacious for use in chronic pain." | 4.12 | Long-term safety and efficacy of sublingual ketamine troches/lozenges in chronic non-malignant pain management. ( Aggarwal, A; Gibson, SB; Maudlin, B, 2022) |
| "Rapid anti-suicidal and antidepressant effects of ketamine have repeatedly been confirmed in unipolar and bipolar depression." | 3.88 | Rapid antidepressant effect of S-ketamine in schizophrenia. ( Bartova, L; Dold, M; Kasper, S; Milenkovic, I; Papageorgiou, K; Weidenauer, A; Willeit, M; Winkler, D, 2018) |
| "We report a case series on the observed effects of low-dose ketamine infusions in 4 critically ill patients with varying complications related to prolonged critical illness." | 3.83 | Low-Dose Ketamine in Chronic Critical Illness. ( Darrah, D; Moitra, A; Moitra, VK; Patel, MK; Wunsch, H, 2016) |
| "Ketamine, its active metabolite norketamine, and the NR2B-selective antagonist traxoprodil (CP-101,606) were tested in rat models of acute antinociception (paw-withdrawal response to heat) and chronic neuropathic pain (spared nerve injury)." | 3.77 | Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. ( Aarts, L; Dahan, A; Morariu, A; Niesters, M; Swartjes, M, 2011) |
| "The aim of the study was to explore the analgesic effect of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine in acute experimental versus chronic spontaneous pain in Complex Regional Pain Syndrome type 1 (CRPS-1) patients." | 3.76 | An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. ( Bauer, M; Dahan, A; Mooren, R; Noppers, I; Olofsen, E; Sarton, E; Sigtermans, M, 2010) |
| "To determine the sensitivity to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia." | 3.74 | Determination of sensitivity of male Wistar rats to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia in comparison with control group. ( Amini, B; Heydarpour, F; Heydarpour, P; Kalantari, S; Rostami, A, 2007) |
| "This prospective audit was undertaken in order to document the analgesic response and adverse effects of concurrent short-term ('burst') triple-agent analgesic (ketamine, an opioid and an anti-inflammatory agent--either steroidal or non-steroidal) administration, for episodes of acute on chronic pain." | 3.73 | Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic pain. ( Ashby, M; Good, P; Goodchild, C; Jackson, K; Tullio, F, 2005) |
| " A 58-year-old man with multiple arthritis of rheumatic arthritis and fibromyalgia had headache, nausea, and vomiting all day after ketamine test." | 3.73 | [Postponed or canceled drug challenge tests and side effects of the test drug--a report of four cases]. ( Ann, Y; Arita, H; Asahara, M; Hanaoka, K; Kawamura, G; Mizuno, J; Sekiyama, H, 2006) |
| "We examined the analgesic effect of racemic ketamine and its 2 enantiomers in 16 female patients (age: 20-29 years) suffering acute pain after oral surgery and in 7 female patients (age: 42-79 years) suffering chronic neuropathic orofacial pain." | 3.69 | Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. ( Mathisen, LC; Skjelbred, P; Skoglund, LA; Øye, I, 1995) |
| "Individuals with chronic PTSD (N=30) were randomly assigned (1:1) to receive six infusions of ketamine (0." | 3.01 | A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. ( Bevilacqua, L; Brallier, J; Charney, DS; Collins, AB; Collins, KA; Corniquel, M; Costi, S; Feder, A; Glasgow, AM; Govindarajulu, U; Horn, SR; Jha, MK; Kautz, M; Murrough, JW; Pietrzak, RH; Rutter, SB, 2021) |
| "Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion (mean difference in Impact of Event Scale-Revised score, 12." | 2.79 | Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. ( Aan Het Rot, M; Charney, DS; Feder, A; Iosifescu, D; Kirkwood, K; Lapidus, KA; Morgan, JE; Murrough, JW; Parides, MK; Perez, AM; Saxena, S; Wan, LB, 2014) |
| "Ketamine is an N-methyl-d-aspartate receptor antagonist that has been shown to be useful in the reduction of acute postoperative pain and analgesic consumption in a variety of surgical interventions with variable routes of administration." | 2.75 | Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. ( Abdu, WA; Beach, ML; Brown, JR; Clark, JA; Loftus, RW; Sengupta, DK; Yeager, MP, 2010) |
| " The objective of the study was to develop a lozenge formulation of ketamine for use in patients with neuropathic pain, and to investigate its storage stability and bioavailability after oral or sublingual administration." | 2.74 | Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study. ( Chong, C; Ilett, KF; Jenkins, B; Page-Sharp, M; Schug, SA, 2009) |
| "Ketamine has been shown to have a morphine-sparing effect soon after surgery." | 2.74 | The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study. ( Baud, A; Couvret, C; Favard, L; Fusciardi, J; Laffon, M; Le Tendre, C; Pourrat, X; Remérand, F, 2009) |
| "0001) with pain relief within 10 min of dosing and lasting for up to 60 min." | 2.71 | Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. ( Albin, R; Brennen, L; Brookoff, D; Carr, DB; Denman, WT; Firestone, L; Goudas, LC; Green, G; Hamilton, D; Lavin, PT; Mermelstein, F; Rogers, MC; Staats, PS, 2004) |
| " Dose-response estimation in 2 patients with PNS-related neuropathic pain revealed that ketamine was effective in dose-related fashion." | 2.67 | Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. ( Arndt, G; Backonja, M; Check, B; Gombar, KA; Zimmermann, M, 1994) |
| "As TR-PTSD has a marked public health burden and significant limitations in terms of treatment interventions, a thorough assessment of current strategies is required." | 2.53 | Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches. ( Kluewer D'Amico, J; Makani, R; Parikh, T; Pradhan, B, 2016) |
| "Abstract Chronic algodystrophy is difficult to treat, because the disease in this stage is usually resistant to many therapies." | 2.50 | Intravenous ketamine infusions for chronic algodystrophy: a review. ( Pastuszka, J; Żyluk, A, 2014) |
| "Chronic neuropathic pain is a debilitating disease caused by a lesion of the somatosensory nervous system." | 2.48 | Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain. ( Dahan, A; Niesters, M, 2012) |
| "Ketamine is an N-methyl-D-aspartate receptor antagonist that has been in clinical use in the USA for over 30 years." | 2.47 | Ketamine in pain management. ( Cohen, SP; Gupta, A; Liao, W; Plunkett, A, 2011) |
| " There was no consistent dose-response relation." | 2.46 | Use of oral ketamine in chronic pain management: a review. ( Blonk, MI; Huygen, FJ; Koder, BG; van den Bemt, PM, 2010) |
| "Neuropathic pain has been known to be refractory to traditional analgesics, such as opioids and non-steroidal anti-inflammatoy drugs." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| "Pain is a multidimensional symptom that can overshadow all other experiences of both the child and family." | 2.44 | The management of pain in children with life-limiting illnesses. ( Friedrichsdorf, SJ; Kang, TI, 2007) |
| "The prevalences of complex regional pain syndrome, phantom limb pain, chronic donor-site pain, and persistent pain following total joint arthroplasty are alarmingly high." | 2.44 | Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. ( Buvanendran, A; Reuben, SS, 2007) |
| "neuropathic pain) is not very satisfactorily managed." | 2.44 | [Central and peripheral mechanisms in antinociception: current and future perspectives]. ( Fürst, Z, 2008) |
| "Ketamine is a dissociative anaesthetic; its mechanism of action is primarily an antagonism of the N-methyl-D-aspartate (NMDA) receptor." | 2.43 | The role of ketamine in pain management. ( Schug, SA; Visser, E, 2006) |
| "Patients with refractory chronic migraine have substantial disability and have failed many acute and preventive medications." | 1.62 | Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis. ( Denk, W; Katz, D; Lauritsen, C; Lovett, J; Moaddel, R; Schwenk, ES; Silberstein, SD; Torjman, MC; Wainer, IW, 2021) |
| "The treatment of ketamine users is substantially challenged by high dropout rates, raising questions regarding contributing factors." | 1.56 | Cognitive impairment in chronic ketamine abusers. ( Hao, W; Tang, WK; Xu, Y; Zhang, B; Zhang, C, 2020) |
| "Refractory chronic cluster headache (CCH) is a rare but highly debilitating condition that needs new treatment options." | 1.56 | Ketamine-Magnesium for Refractory Chronic Cluster Headache: A Case Series. ( Ciampi de Andrade, D; Clavelou, P; Condé, S; Dallel, R; Giraud, P; Meunier, E; Moisset, X; Pereira, B; Périé, M; Picard, P, 2020) |
| "Treatment with ketamine, minocycline and amitriptyline were able to exert antidepressant effects in the forced swimming test." | 1.48 | Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events. ( Abelaira, HM; de Moura, AB; de Souza, TG; Fileti, ME; Garbossa, L; Goldim, MP; Maciel, AL; Mathias, K; Matos, D; Petronilho, F; Quevedo, J; Réus, GZ; Rosa, T; Strassi, AP; Tuon, T, 2018) |
| "(R)-Ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine." | 1.48 | Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model. ( Dong, C; Hashimoto, K; Ma, M; Qu, Y; Ren, Q; Yang, C; Zhang, JC, 2018) |
| "Schizophrenia is a chronic and devastating disease with an overall lifetime risk of 1%." | 1.46 | Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. ( Hauser, MJ; Isbrandt, D; Roeper, J, 2017) |
| "Refractory migraine is a challenging condition with great impact on health related quality of life." | 1.43 | Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. ( Ashina, S; Lauritsen, C; Lipton, RB; Mazuera, S, 2016) |
| "Ketamine is a centrally acting agent believed to work through blockade of N-methyl-D- aspartate receptors and is being increasingly used for the treatment of refractory CRPS, although the basis for the drug's effects and efficacy at different stages of the syndrome remains unclear." | 1.42 | Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice. ( Clark, JD; Huang, TT; Kingery, WS; Leu, D; Tajerian, M; Yang, P, 2015) |
| "Ketamine has proposed anti-inflammatory effects and has been used for treating CRPS." | 1.42 | Preventive Treatment with Ketamine Attenuates the Ischaemia-Reperfusion Response in a Chronic Postischaemia Pain Model. ( Cheung, CW; Choi, SW; Irwin, M; Liman, S; Ng, KF; Qiu, Q; Tai, W; Wong, KL, 2015) |
| "Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has been found to induce schizophrenia-type symptoms in humans and is a potent and fast-acting antidepressant." | 1.40 | Abnormalities in white matter microstructure associated with chronic ketamine use. ( Curran, HV; Edward Roberts, R; Friston, KJ; Morgan, CJ, 2014) |
| "It had less effect on tactile allodynia (CCI)." | 1.35 | Effects of norketamine enantiomers in rodent models of persistent pain. ( Crooks, PA; Hojomat, M; Holtman, JR; Johnson-Hardy, JK; Kleven, M; Wala, EP, 2008) |
| "Glycine (GLY), which acts as an obligatory co-agonist at the NMDAR-GLY site, induces PPI deficits in rats although, consistent with the hypo-NMDAR hypothesis, improves negative and cognitive symptoms in schizophrenia patients." | 1.34 | High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. ( Bar, G; Ebstein, RP; Ermilov, M; Heresco-Levy, U; Javitt, DC; Levin, R, 2007) |
| "Neuropathic pain has been shown to respond to drugs that block the N-methyl-D-aspartate (NMDA) receptor, such as ketamine and amantidine." | 1.31 | An unusual case of chronic neuropathic pain responds to an optimum frequency of intravenous ketamine infusions. ( Mitchell, AC, 2001) |
| "Ketamine is an injectable anesthetic induction agent that has been reported to have analgesic activity in pain from a variety of mechanisms, but predominantly in neuralgic and dysesthetic neuropathic pain." | 1.30 | Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. ( Fisher, K; Hagen, NA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (4.13) | 18.7374 |
| 1990's | 15 (12.40) | 18.2507 |
| 2000's | 45 (37.19) | 29.6817 |
| 2010's | 47 (38.84) | 24.3611 |
| 2020's | 9 (7.44) | 2.80 |
| Authors | Studies |
|---|---|
| Petersen, AS | 1 |
| Pedersen, AS | 1 |
| Barloese, MCJ | 1 |
| Holm, P | 1 |
| Pedersen, O | 1 |
| Jensen, RH | 1 |
| Snoer, AH | 1 |
| Talbot, J | 1 |
| Phillips, JL | 1 |
| Blier, P | 1 |
| Fan, N | 1 |
| An, L | 1 |
| Zhang, M | 1 |
| He, H | 1 |
| Zhou, Y | 1 |
| Ou, Y | 1 |
| Averill, LA | 1 |
| Fouda, S | 1 |
| Murrough, JW | 3 |
| Abdallah, CG | 1 |
| Elhussiny, MEA | 1 |
| Carini, G | 1 |
| Mingardi, J | 1 |
| Tornese, P | 1 |
| Sala, N | 1 |
| Bono, F | 1 |
| Fiorentini, C | 1 |
| La Via, L | 1 |
| Popoli, M | 1 |
| Musazzi, L | 1 |
| Barbon, A | 1 |
| Zhang, C | 1 |
| Xu, Y | 1 |
| Zhang, B | 1 |
| Hao, W | 1 |
| Tang, WK | 1 |
| Moisset, X | 1 |
| Giraud, P | 1 |
| Meunier, E | 1 |
| Condé, S | 1 |
| Périé, M | 1 |
| Picard, P | 1 |
| Pereira, B | 1 |
| Ciampi de Andrade, D | 1 |
| Clavelou, P | 1 |
| Dallel, R | 1 |
| Feder, A | 2 |
| Costi, S | 1 |
| Rutter, SB | 1 |
| Collins, AB | 1 |
| Govindarajulu, U | 1 |
| Jha, MK | 1 |
| Horn, SR | 1 |
| Kautz, M | 1 |
| Corniquel, M | 1 |
| Collins, KA | 1 |
| Bevilacqua, L | 1 |
| Glasgow, AM | 1 |
| Brallier, J | 1 |
| Pietrzak, RH | 1 |
| Charney, DS | 2 |
| Maudlin, B | 1 |
| Gibson, SB | 1 |
| Aggarwal, A | 1 |
| Schwenk, ES | 1 |
| Torjman, MC | 1 |
| Moaddel, R | 1 |
| Lovett, J | 1 |
| Katz, D | 1 |
| Denk, W | 1 |
| Lauritsen, C | 2 |
| Silberstein, SD | 1 |
| Wainer, IW | 1 |
| Lee, HG | 1 |
| Grossman, SK | 1 |
| Valdes-Rodriguez, R | 1 |
| Berenato, F | 1 |
| Korbutov, J | 1 |
| Chan, YH | 1 |
| Lavery, MJ | 1 |
| Yosipovitch, G | 1 |
| Rincón-Cortés, M | 1 |
| Grace, AA | 1 |
| Hauser, MJ | 1 |
| Isbrandt, D | 1 |
| Roeper, J | 1 |
| Yang, C | 2 |
| Ren, Q | 1 |
| Qu, Y | 1 |
| Zhang, JC | 1 |
| Ma, M | 1 |
| Dong, C | 1 |
| Hashimoto, K | 3 |
| Liu, SYW | 1 |
| Ng, SKK | 1 |
| Tam, YH | 1 |
| Yee, SCH | 1 |
| Lai, FPT | 1 |
| Hong, CYL | 1 |
| Chiu, PWY | 1 |
| Ng, EKW | 1 |
| Ng, CF | 1 |
| Wilkinson, ST | 1 |
| Sanacora, G | 1 |
| Maciel, AL | 1 |
| Abelaira, HM | 1 |
| de Moura, AB | 1 |
| de Souza, TG | 1 |
| Rosa, T | 1 |
| Matos, D | 1 |
| Tuon, T | 1 |
| Garbossa, L | 1 |
| Strassi, AP | 1 |
| Fileti, ME | 1 |
| Goldim, MP | 1 |
| Mathias, K | 1 |
| Petronilho, F | 1 |
| Quevedo, J | 1 |
| Réus, GZ | 1 |
| Bartova, L | 1 |
| Papageorgiou, K | 1 |
| Milenkovic, I | 1 |
| Dold, M | 1 |
| Weidenauer, A | 1 |
| Willeit, M | 1 |
| Winkler, D | 1 |
| Kasper, S | 1 |
| Poterucha, TJ | 1 |
| Murphy, SL | 1 |
| Sandroni, P | 1 |
| Rho, RH | 1 |
| Warndahl, RA | 1 |
| Weiss, WT | 1 |
| Davis, MD | 1 |
| Ram, E | 1 |
| Raphaeli, S | 1 |
| Avital, A | 1 |
| Edward Roberts, R | 1 |
| Curran, HV | 2 |
| Friston, KJ | 1 |
| Morgan, CJ | 2 |
| De Gioannis, A | 1 |
| De Leo, D | 1 |
| Connors, NJ | 1 |
| Grino, A | 1 |
| Tunik, MG | 1 |
| Hoffman, RS | 1 |
| Żyluk, A | 1 |
| Pastuszka, J | 1 |
| Parides, MK | 1 |
| Perez, AM | 1 |
| Morgan, JE | 1 |
| Saxena, S | 1 |
| Kirkwood, K | 1 |
| Aan Het Rot, M | 1 |
| Lapidus, KA | 1 |
| Wan, LB | 1 |
| Iosifescu, D | 1 |
| Anticevic, A | 1 |
| Corlett, PR | 1 |
| Cole, MW | 1 |
| Savic, A | 1 |
| Gancsos, M | 1 |
| Tang, Y | 1 |
| Repovs, G | 1 |
| Murray, JD | 1 |
| Driesen, NR | 1 |
| Morgan, PT | 1 |
| Xu, K | 1 |
| Wang, F | 1 |
| Krystal, JH | 1 |
| Franceschelli, A | 1 |
| Sens, J | 1 |
| Herchick, S | 1 |
| Thelen, C | 1 |
| Pitychoutis, PM | 1 |
| Kim, YH | 1 |
| Lee, PB | 1 |
| Oh, TK | 1 |
| Moitra, VK | 1 |
| Patel, MK | 1 |
| Darrah, D | 1 |
| Moitra, A | 1 |
| Wunsch, H | 1 |
| McCaffrey, N | 1 |
| Hardy, J | 1 |
| Fazekas, B | 1 |
| Agar, M | 1 |
| Devilee, L | 1 |
| Rowett, D | 1 |
| Currow, D | 1 |
| Liman, S | 1 |
| Cheung, CW | 1 |
| Wong, KL | 1 |
| Tai, W | 1 |
| Qiu, Q | 1 |
| Ng, KF | 1 |
| Choi, SW | 1 |
| Irwin, M | 1 |
| Pradhan, B | 1 |
| Kluewer D'Amico, J | 1 |
| Makani, R | 1 |
| Parikh, T | 1 |
| Tang, J | 1 |
| Xue, W | 1 |
| Xia, B | 1 |
| Ren, L | 1 |
| Tao, W | 1 |
| Chen, C | 1 |
| Zhang, H | 1 |
| Wu, R | 1 |
| Wang, Q | 1 |
| Wu, H | 1 |
| Duan, J | 1 |
| Chen, G | 1 |
| Tajerian, M | 1 |
| Leu, D | 1 |
| Yang, P | 1 |
| Huang, TT | 1 |
| Kingery, WS | 1 |
| Clark, JD | 2 |
| Liu, WX | 1 |
| Wang, J | 1 |
| Xie, ZM | 1 |
| Xu, N | 1 |
| Zhang, GF | 2 |
| Jia, M | 1 |
| Zhou, ZQ | 2 |
| Yang, JJ | 2 |
| Stepan, J | 1 |
| Hladky, F | 1 |
| Uribe, A | 1 |
| Holsboer, F | 1 |
| Schmidt, MV | 1 |
| Eder, M | 1 |
| Amat, J | 1 |
| Dolzani, SD | 1 |
| Tilden, S | 1 |
| Christianson, JP | 1 |
| Kubala, KH | 1 |
| Bartholomay, K | 1 |
| Sperr, K | 1 |
| Ciancio, N | 1 |
| Watkins, LR | 1 |
| Maier, SF | 1 |
| Sun, HL | 1 |
| Wang, XM | 1 |
| Shen, JC | 1 |
| Mazuera, S | 1 |
| Lipton, RB | 1 |
| Ashina, S | 1 |
| Hanaoka, K | 2 |
| Arita, H | 2 |
| Nagase, M | 1 |
| Ide, Y | 1 |
| Tagami, M | 1 |
| Hayashida, M | 1 |
| Castrillon, EE | 1 |
| Cairns, BE | 1 |
| Ernberg, M | 1 |
| Wang, K | 1 |
| Sessle, BJ | 1 |
| Arendt-Nielsen, L | 3 |
| Svensson, P | 1 |
| Holtman, JR | 1 |
| Crooks, PA | 1 |
| Johnson-Hardy, JK | 1 |
| Hojomat, M | 1 |
| Kleven, M | 1 |
| Wala, EP | 1 |
| Cohen, SP | 3 |
| Wang, S | 1 |
| Chen, L | 1 |
| Kurihara, C | 1 |
| McKnight, G | 1 |
| Marcuson, M | 1 |
| Mao, J | 1 |
| Yamamoto, T | 1 |
| Fürst, Z | 1 |
| Crousier, M | 1 |
| Cognet, V | 1 |
| Khaled, M | 1 |
| Gueugniaud, PY | 1 |
| Piriou, V | 1 |
| Bell, RF | 2 |
| Mion, G | 1 |
| Libert, N | 1 |
| Cirodde, A | 1 |
| Tourtier, JP | 1 |
| Rousseau, JM | 1 |
| Chong, C | 1 |
| Schug, SA | 2 |
| Page-Sharp, M | 1 |
| Jenkins, B | 1 |
| Ilett, KF | 1 |
| Sigtermans, M | 2 |
| Noppers, I | 3 |
| Sarton, E | 3 |
| Bauer, M | 2 |
| Mooren, R | 1 |
| Olofsen, E | 2 |
| Dahan, A | 5 |
| Borsook, D | 1 |
| Kapoor, SG | 1 |
| Rathmell, JP | 1 |
| Chen, LY | 1 |
| Chen, KP | 1 |
| Huang, MC | 1 |
| Sen, H | 1 |
| Sizlan, A | 1 |
| Yanarates, O | 1 |
| Emirkadi, H | 1 |
| Ozkan, S | 1 |
| Dagli, G | 1 |
| Turan, A | 1 |
| Blonk, MI | 1 |
| Koder, BG | 1 |
| van den Bemt, PM | 1 |
| Huygen, FJ | 1 |
| Remérand, F | 1 |
| Le Tendre, C | 1 |
| Baud, A | 1 |
| Couvret, C | 1 |
| Pourrat, X | 1 |
| Favard, L | 1 |
| Laffon, M | 1 |
| Fusciardi, J | 1 |
| Boettger, MK | 1 |
| Weber, K | 1 |
| Gajda, M | 1 |
| Bräuer, R | 1 |
| Schaible, HG | 2 |
| Ahmadi, A | 1 |
| Khalili, M | 1 |
| Mihandoust, F | 1 |
| Barghi, L | 1 |
| Kapural, L | 1 |
| Stanton-Hicks, M | 1 |
| Poon, P | 1 |
| Jackson, K | 2 |
| Platt, T | 1 |
| Niesters, M | 4 |
| Aarts, L | 3 |
| Angst, MS | 1 |
| Loftus, RW | 1 |
| Yeager, MP | 1 |
| Clark, JA | 2 |
| Brown, JR | 1 |
| Abdu, WA | 1 |
| Sengupta, DK | 1 |
| Beach, ML | 1 |
| Smith, T | 1 |
| Liao, W | 1 |
| Gupta, A | 1 |
| Plunkett, A | 1 |
| Seigne, RD | 1 |
| Swartjes, M | 1 |
| Morariu, A | 1 |
| Sun, L | 1 |
| Li, Q | 2 |
| Zhang, Y | 1 |
| Liu, D | 1 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Yew, DT | 1 |
| Furuhashi-Yonaha, A | 1 |
| Iida, H | 1 |
| Asano, T | 1 |
| Takeda, T | 1 |
| Dohi, S | 1 |
| Miles, J | 1 |
| Chang, FL | 1 |
| Huang, GS | 1 |
| Cherng, CH | 1 |
| Ho, ST | 1 |
| Wong, CS | 1 |
| Pelissier, T | 1 |
| Alvarez, P | 1 |
| Hernández, A | 1 |
| Hocking, G | 1 |
| Cousins, MJ | 1 |
| Mannion, S | 1 |
| O'Brien, T | 1 |
| Miyamoto, E | 1 |
| Nakao, S | 1 |
| Tomimoto, H | 1 |
| Wakita, H | 1 |
| Yamada, M | 1 |
| Masuzawa, M | 1 |
| Takahira, K | 1 |
| Sakamoto, S | 1 |
| Shingu, K | 1 |
| Kalso, E | 1 |
| Carr, DB | 2 |
| Goudas, LC | 2 |
| Denman, WT | 2 |
| Brookoff, D | 2 |
| Staats, PS | 2 |
| Brennen, L | 1 |
| Green, G | 1 |
| Albin, R | 1 |
| Hamilton, D | 1 |
| Rogers, MC | 1 |
| Firestone, L | 1 |
| Lavin, PT | 2 |
| Mermelstein, F | 1 |
| Blackburn, JP | 1 |
| Lynch, EM | 1 |
| Kwok, RKF | 1 |
| Chan, MTV | 1 |
| Gin, T | 1 |
| Good, P | 1 |
| Tullio, F | 1 |
| Goodchild, C | 1 |
| Ashby, M | 1 |
| Pasero, C | 1 |
| McCaffery, M | 1 |
| Tao, Y | 1 |
| Chen, XP | 1 |
| Qin, ZH | 1 |
| Clatts, MC | 1 |
| Goldsamt, LA | 1 |
| Yi, H | 1 |
| Mizuno, J | 1 |
| Ann, Y | 1 |
| Kawamura, G | 1 |
| Asahara, M | 1 |
| Sekiyama, H | 1 |
| Visser, E | 1 |
| Lemming, D | 1 |
| Sörensen, J | 1 |
| Graven-Nielsen, T | 1 |
| Lauber, R | 1 |
| Gerdle, B | 1 |
| Heresco-Levy, U | 1 |
| Bar, G | 1 |
| Levin, R | 1 |
| Ermilov, M | 1 |
| Ebstein, RP | 1 |
| Javitt, DC | 1 |
| Ben-Ari, A | 1 |
| Lewis, MC | 1 |
| Davidson, E | 1 |
| Reuben, SS | 1 |
| Buvanendran, A | 1 |
| Heydarpour, F | 1 |
| Amini, B | 1 |
| Kalantari, S | 1 |
| Rostami, A | 1 |
| Heydarpour, P | 1 |
| Friedrichsdorf, SJ | 1 |
| Kang, TI | 1 |
| Haugan, F | 1 |
| Rygh, LJ | 1 |
| Tjølsen, A | 1 |
| Constantinides, CG | 1 |
| Nixon, HH | 1 |
| Vatashsky, E | 1 |
| Aronson, HB | 1 |
| Mathisen, LC | 1 |
| Skjelbred, P | 2 |
| Skoglund, LA | 1 |
| Øye, I | 2 |
| Persson, J | 1 |
| Axelsson, G | 1 |
| Hallin, RG | 1 |
| Gustafsson, LL | 1 |
| Neugebauer, V | 1 |
| Lücke, T | 1 |
| Grubb, B | 1 |
| Backonja, M | 1 |
| Arndt, G | 1 |
| Gombar, KA | 1 |
| Check, B | 1 |
| Zimmermann, M | 1 |
| Felsby, S | 1 |
| Nielsen, J | 1 |
| Jensen, TS | 1 |
| Stubhaug, A | 2 |
| Breivik, H | 2 |
| Meller, ST | 1 |
| Eide, PK | 1 |
| Oye, I | 3 |
| Nicolodi, M | 1 |
| Del Bianco, PL | 1 |
| Sicuteri, F | 1 |
| Karpinski, N | 1 |
| Dunn, J | 1 |
| Hansen, L | 1 |
| Masliah, E | 1 |
| Mills, IH | 1 |
| Park, GR | 1 |
| Manara, AR | 1 |
| Merriman, RJ | 1 |
| Rabben, T | 2 |
| Enarson, MC | 1 |
| Hays, H | 1 |
| Woodroffe, MA | 1 |
| Fisher, K | 1 |
| Hagen, NA | 1 |
| Welte, T | 1 |
| Mitchell, AC | 1 |
| Bruins Slot, LA | 1 |
| Tarayre, JP | 1 |
| Koek, W | 1 |
| Ribet, JP | 1 |
| Colpaert, FC | 1 |
| Heilmann, K | 1 |
| Stoelting, RK | 1 |
| Gadalov, VP | 1 |
| Kuz'mina, EG | 1 |
| Fedotova, LIa | 1 |
| Burenkova, LK | 1 |
| Smirnova, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD[NCT06036511] | Phase 1/Phase 2 | 14 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Randomized Controlled Trial of Repeated-Dose Intravenous Ketamine for PTSD[NCT02397889] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2015-05-18 | Completed | ||
| Impact of Night-time Dexmedetomidine-esketamine Infusion on Sleep Quality of Patients With Mechanical Ventilation in ICU: a Randomized Controlled Trial[NCT05718024] | Phase 4 | 174 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study[NCT06003218] | 88 participants (Anticipated) | Interventional | 2023-10-16 | Recruiting | |||
| Effects of Low-dose Dexmedetomidine-esketamine Combined Nasal Administration at Night on Perioperative Sleep Quality in Breast Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial[NCT05732064] | Phase 4 | 180 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| Effects of Low-dose S-ketamine on the Incidence of Postpartum Depression in Women With Prenatal Depression: a Randomized, Double-blind, Placebo-controlled Trial[NCT04414943] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Patient-controlled Analgesia After Scoliosis Correction Surgery: a Randomized, Double-blind, Placebo-controlled Trial[NCT04791059] | Phase 4 | 200 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Effect of Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia on Long-term Outcomes Following Scoliosis Correction Surgery: 2-year Follow-up of a Randomized Controlled Trial[NCT05718544] | Phase 4 | 199 participants (Actual) | Interventional | 2023-01-30 | Active, not recruiting | ||
| Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder[NCT00749203] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain Patients[NCT04322968] | Phase 3 | 41 participants (Actual) | Interventional | 2018-01-09 | Completed | ||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Assessing a Combined Ketamine and Online Cognitive Behavioural Therapy Intervention for Treatment Resistant Post-Traumatic Stress Disorder[NCT04771767] | Phase 2 | 16 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384] | 30 participants (Actual) | Observational | 2016-11-28 | Completed | |||
| Ketamine and Mindfulness Based Cognitive Therapy (MBCT) in Treatment of Post-Traumatic Stress Disorder (PTSD): Comparison of Treatment Efficacy and Metabolomic Profiles[NCT02766192] | 50 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | |||
| Pathophysiological Understanding and Treatment of PTSD: an rTMS Approach[NCT03840369] | 25 participants (Actual) | Interventional | 2020-06-01 | Completed | |||
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia[NCT02397356] | Phase 4 | 0 participants (Actual) | Interventional | 2018-08-31 | Withdrawn (stopped due to Lack of study personnel) | ||
| The Effect of Intravenous Infusions of Lidocaine and Magnesium Versus Lidocaine and Ketamine Versus Lidocaine Alone on Recovery Profile and Postoperative Pain After Elective Gynecological Surgery[NCT04622904] | 90 participants (Anticipated) | Interventional | 2020-11-14 | Recruiting | |||
| Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia[NCT03066739] | Phase 2 | 105 participants (Anticipated) | Interventional | 2023-02-25 | Recruiting | ||
| Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients[NCT02160301] | Phase 4 | 0 participants (Actual) | Interventional | 2017-11-30 | Withdrawn (stopped due to Insufficient infrastructure/funding for enrollment) | ||
| The Effect and Contribution of a Perioperative Ketamine Infusion in an Established Enhanced Recovery Pathway[NCT04625283] | Phase 4 | 1,544 participants (Anticipated) | Interventional | 2021-04-12 | Enrolling by invitation | ||
| Prospective Randomized Double Blind Study of Intraoperative Dexmedetomidine and Postoperative Pain Control in Patients Undergoing Multi-level Thoraco-lumbar Spine Surgery[NCT01850017] | Phase 4 | 142 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients[NCT02085577] | Phase 4 | 147 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Prospective, Block Randomized, Double-Blind Placebo-Controlled Trial of Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion[NCT02378740] | Phase 4 | 0 participants (Actual) | Interventional | 2015-04-30 | Withdrawn (stopped due to PI has left the University) | ||
| Efficacy of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery: A Randomized, Double-blind Trial[NCT06062550] | Phase 4 | 312 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Impact of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia on Long-term Outcomes After Scoliosis Correction Surgery: Follow-up of a Randomized Trial[NCT06087510] | Phase 4 | 312 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A Prospective, Randomized, Single Blinded Comparison of Intraoperative Ketamine Infusion Versus Placebo in Patients Having Spinal Fusion[NCT02424591] | Phase 4 | 46 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.[NCT02657031] | Phase 4 | 54 participants (Actual) | Interventional | 2016-03-17 | Completed | ||
| Spreading Depolarization and Ketamine Suppression[NCT02501941] | Phase 1 | 10 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Prehospital Analgesia With Intra-Nasal Ketamine[NCT02753114] | Phase 4 | 120 participants (Actual) | Interventional | 2017-11-06 | Completed | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| A Randomized Controlled Trial to Determine the Efficacy of Ketamine as an Adjunct for Pain Management in Patients With Sickle Cell Crisis[NCT03502421] | Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to Never IRB approved, no intention to proceed with the study) | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Naloxone Block of Low-dose (Analgetic Dose) Ketamine[NCT00921765] | Phase 4 | 3 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to Problems with patient recruitment) | ||
| Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325] | Phase 3 | 24 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy.[NCT00313378] | Phase 3 | 78 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Magnesium Oral Supplementation to Reduce Pain in Patients With Severe Peripheral Arterial Occlusive Disease: The MAG-PAPER Randomized Clinical Trial[NCT02455726] | 150 participants (Anticipated) | Interventional | 2015-09-30 | Not yet recruiting | |||
| Starving for Energy - A Pilot Study to Test Ketone Derived Energy in Eating Disorders[NCT05507008] | 40 participants (Anticipated) | Interventional | 2022-10-13 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
full range score from 0-80, with higher scores indicating greater PTSD symptoms (NCT02397889)
Timeframe: 2 weeks after the first infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 22.5 |
| Active Control Midazolam Group | 33.2 |
full range score from 0-60, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 2 weeks after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 14.7 |
| Active Control Midazolam Group | 21.9 |
full range score from 0-60, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 24 hours after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 16.5 |
| Active Control Midazolam Group | 17.1 |
All side effects listed in Adverse Event section. (NCT02397889)
Timeframe: up to 21 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Ketamine Group | 15 |
| Active Control Midazolam Group | 15 |
full range score from 0-27, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 2 weeks after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 6.6 |
| Active Control Midazolam Group | 6.7 |
full range score from 0-88, with higher scores indicating greater PTSD symptoms (NCT02397889)
Timeframe: 24 hours after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 19.7 |
| Active Control Midazolam Group | 24.8 |
Clinician-administered structured interview measuring PTSD symptoms. frequency score - scale 0 = none of the time to 4 = most or all of the time intensity score - scale 0 = none to 4 = extreme To meet criteria for a symptom, a patient must meet criteria in both frequency and intensity score for each item. Frequency and intensity and then combined to form a single severity score. 30 questions scale, with total score ranging from 0 to 240. (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 54 |
| Midazolam | 65.69 |
"A 22-item self-report questionnaire measuring PTSD symptoms. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score ranging from 0 (not at all) to 88 (extremely)" (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 25.76 |
| Midazolam | 36.32 |
Clinician-administered questionnaire measuring depressive symptoms. The MADRS-S has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). Mean difference between baseline and 2 weeks. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.6 |
| Midazolam | 10.1 |
Self-report questionnaire measuring depressive symptoms. Each item is rated 0 (no depression) to 3 (severe depression). The total score ranges from 0-27. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.4 |
| Midazolam | 11.3 |
"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms" (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 28.22 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 33.66666667 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 11.44 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 13.41 |
"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms" (NCT04322968)
Timeframe: 24 hrs post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 36.33333333 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 37 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 10.44444444 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 15.64705882 |
"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity." (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 48.22 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 52.88 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 43.33 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 48.23 |
"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity." (NCT04322968)
Timeframe: 24 hrs post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 37.22222222 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 49.66666667 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 29.88888889 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 38.70588235 |
"Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week; No scoring algorithm, but worst pain or the arithmetic mean of the four severity items can be used as measures of pain severity (a range of 0-10, with 10 being worse scores); the arithmetic mean of the seven interference items can be used as a measure of pain interference (a range of 0-10, with 10 being worse scores). The total score is reported for severity items and interference items, which range from 0-40 and 0-70, respectively. Higher values represent worse outcome." (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Pain interference Scale | Pain severity Scale | |
| Chronic Pain With PTSD+IV Ketamine Infusion | 38.62 | 20.75 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 25.66 | 14.66 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 9.62 | 12.75 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 28.33 | 22.66 |
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
"Beck's Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures attitudes and symptoms of depression. Each sentence has a rating from 0 to 3 and the sentences go from mild to fairly severe descriptions of moods. The numbers are tabulated, the lowest possible score is 0 and the highest is 63.~A score of 1-10 indicates normal ups and downs. 11-16 indicates a mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; over 40, extreme depression" (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 8 |
| Placebo | 9 |
"McGill Short Form measures pain in different ways. The first part of the form lists 15 adjectives for pain, for which the answers can be none (0), Mild (1), Moderate (2) and Severe (3). Descriptors 1-11 represent the sensory dimension of pain experience and 12-15 represent the affective dimension. A score of 0 is good, and a score of 45 indicates extreme pain. The lower the score the less pain a subject feels (better), as the scores go up, so do the pain levels (worse).~PPI (Present Pain Intensity) asks patients to measure pain from 0 (no pain) to 5 (excruciating). Again, a lower score is ideal." (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 11 |
| Placebo | 10.5 |
Quality of Recovery 15 questions questionnaires that ask, on a scale of 0-10, with 0 always being bad and 10 always being best, how the patient is recovering. The total number is reviewed, so the highest total score possible is 150 and the lowest is 0. (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 95 |
| Placebo | 101 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 33.7 |
| Study Arm | 21.2 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 63.5 |
| Study Arm | 43.5 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 38.9 |
| Study Arm | 22.9 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 2 |
| Study Arm | 3 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 3 |
| Study Arm | 3 |
25 reviews available for ketamine and Chronic Disease
| Article | Year |
|---|---|
Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence.
Topics: Antidepressive Agents; Chronic Disease; Depressive Disorder, Major; Humans; Ketamine; Nerve Net; Str | 2020 |
Intravenous ketamine infusions for chronic algodystrophy: a review.
Topics: Chronic Disease; Excitatory Amino Acid Antagonists; Humans; Infusions, Intravenous; Ketamine; Neural | 2014 |
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches.
Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H | 2016 |
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches.
Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H | 2016 |
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches.
Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H | 2016 |
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches.
Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H | 2016 |
[Selection of drugs suitable for the treatment of intractable chronic pain patients by using drug challenge tests].
Topics: Alprostadil; Analgesics; Barbiturates; Benzodiazepines; Chronic Disease; Humans; Ketamine; Lidocaine | 2008 |
[Mechanisms of the development of neuropathic pain and its treatment].
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Block | 2008 |
[Central and peripheral mechanisms in antinociception: current and future perspectives].
Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocycl | 2008 |
Ketamine for chronic non-cancer pain.
Topics: Analgesics; Animals; Chronic Disease; Drug Administration Routes; Humans; Ketamine; Pain | 2009 |
Ketamine for chronic non-cancer pain.
Topics: Analgesics; Animals; Chronic Disease; Drug Administration Routes; Humans; Ketamine; Pain | 2009 |
Ketamine for chronic non-cancer pain.
Topics: Analgesics; Animals; Chronic Disease; Drug Administration Routes; Humans; Ketamine; Pain | 2009 |
Ketamine for chronic non-cancer pain.
Topics: Analgesics; Animals; Chronic Disease; Drug Administration Routes; Humans; Ketamine; Pain | 2009 |
Intravenous infusion tests have limited utility for selecting long-term drug therapy in patients with chronic pain: a systematic review.
Topics: Adrenergic alpha-Antagonists; Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Local; Chr | 2009 |
Use of oral ketamine in chronic pain management: a review.
Topics: Administration, Oral; Analgesics; Chronic Disease; Humans; Ketamine; Pain | 2010 |
Ketamine for the treatment of chronic non-cancer pain.
Topics: Analgesics; Chronic Disease; Humans; Infusions, Intravenous; Ketamine; Pain; Pain Measurement; Recep | 2010 |
Ketamine in pain management.
Topics: Analgesics; Analgesics, Opioid; Chronic Disease; Drug Therapy, Combination; Humans; Ketamine; Pain | 2011 |
Ketamine use: a review.
Topics: Abdominal Pain; Acute Disease; Anesthetics, Dissociative; Animals; Behavior, Addictive; Child; Chron | 2012 |
Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain.
Topics: Animals; Chronic Disease; Disease Models, Animal; Humans; Ketamine; Neuralgia; Randomized Controlled | 2012 |
Intrathecal therapy for chronic pain.
Topics: Administration, Oral; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Disease; Hum | 2001 |
Ketamine in chronic pain management: an evidence-based review.
Topics: Chronic Disease; Evidence-Based Medicine; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pain | 2003 |
Ketamine in chronic pain management: an evidence-based review.
Topics: Chronic Disease; Evidence-Based Medicine; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pain | 2003 |
Ketamine in chronic pain management: an evidence-based review.
Topics: Chronic Disease; Evidence-Based Medicine; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pain | 2003 |
Ketamine in chronic pain management: an evidence-based review.
Topics: Chronic Disease; Evidence-Based Medicine; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pain | 2003 |
Is intranasal ketamine an appropriate treatment for chronic non-cancer breakthrough pain?
Topics: Administration, Intranasal; Analgesics; Chronic Disease; Humans; Ketamine; Pain | 2004 |
Should ketamine be used as a regular analgesic for patients with chronic pain?
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Pain | 2004 |
Pain control: ketamine: low doses may provide relief for some painful conditions.
Topics: Analgesics; Chronic Disease; Drug Monitoring; Humans; Ketamine; Neoplasms; Pain | 2005 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
Chronic administration of ketamine for analgesia.
Topics: Analgesics; Animals; Chronic Disease; Humans; Ketamine; Neoplasms; Pain, Intractable; Peripheral Ner | 2007 |
Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques.
Topics: Acetaminophen; Adrenergic alpha-Agonists; Analgesia, Epidural; Analgesics; Anesthetics, Local; Anima | 2007 |
The management of pain in children with life-limiting illnesses.
Topics: Analgesics, Opioid; Child; Chronic Disease; Codeine; Fentanyl; Humans; Hydromorphone; Ketamine; Meth | 2007 |
[Drug therapy in acute and chronic respiratory insufficiency].
Topics: Acetylcysteine; Acute Disease; Analgesics; Anti-Bacterial Agents; Bronchodilator Agents; Cholinergic | 2001 |
[Glaucoma, tonometry and anaesthesia (author's transl)].
Topics: Anesthesia; Anesthetics; Blood Pressure; Chronic Disease; Eye; Glaucoma; Humans; Intraocular Pressur | 1975 |
Current views on the role of opioid receptors and endorphins in anesthesiology.
Topics: Acute Disease; Anesthesia; Animals; Blood Circulation; Chronic Disease; Endorphins; Halothane; Human | 1986 |
20 trials available for ketamine and Chronic Disease
| Article | Year |
|---|---|
Intranasal ketamine for acute cluster headache attacks-Results from a proof-of-concept open-label trial.
Topics: Administration, Intranasal; Adult; Analgesics; Chronic Disease; Cluster Headache; Female; Humans; Ke | 2022 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Is magnesium sulfate effective for pain in chronic postherpetic neuralgia patients comparing with ketamine infusion therapy?
Topics: Aged; Aged, 80 and over; Analgesics; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies | 2015 |
Effect of peripheral NMDA receptor blockade with ketamine on chronic myofascial pain in temporomandibular disorder patients: a randomized, double-blinded, placebo-controlled trial.
Topics: Adult; Analysis of Variance; Anesthetics, Dissociative; Bite Force; Chronic Disease; Double-Blind Me | 2008 |
[Effect of ketamine on prevention of postmastectomy chronic pain. A pilot study].
Topics: Analgesics; Chronic Disease; Double-Blind Method; Feasibility Studies; Female; Humans; Ketamine; Mas | 2008 |
Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Analgesics; Area Under Curve; Biologi | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Analgesia; Analgesia, Patient-Controlled; Analgesics; Ana | 2009 |
The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Analgesia; Analgesia, Patient-Controlled; Analgesics; Ana | 2009 |
The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Analgesia; Analgesia, Patient-Controlled; Analgesics; Ana | 2009 |
The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Analgesia; Analgesia, Patient-Controlled; Analgesics; Ana | 2009 |
Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain.
Topics: Adult; Analgesia; Analgesics; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Ket | 2011 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.
Topics: Adult; Aged; Analgesics, Opioid; Back Pain; Chronic Disease; Double-Blind Method; Elective Surgical | 2010 |
Short- and long-term efficacy of oral ketamine in eight chronic-pain patients.
Topics: Administration, Oral; Adult; Aged; Analgesics; Chronic Disease; Excitatory Amino Acid Antagonists; F | 2002 |
Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Administration, Intranasal; Adult; Aged; Analgesics; Analgesics, Opioid; Chronic Disease; Cross-Over | 2004 |
Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Administration, Intranasal; Adult; Aged; Analgesics; Analgesics, Opioid; Chronic Disease; Cross-Over | 2004 |
Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Administration, Intranasal; Adult; Aged; Analgesics; Analgesics, Opioid; Chronic Disease; Cross-Over | 2004 |
Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Administration, Intranasal; Adult; Aged; Analgesics; Analgesics, Opioid; Chronic Disease; Cross-Over | 2004 |
Managing chronic whiplash associated pain with a combination of low-dose opioid (remifentanil) and NMDA-antagonist (ketamine).
Topics: Adult; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, C | 2007 |
Response of chronic neuropathic pain syndromes to ketamine: a preliminary study.
Topics: Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; | 1994 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions.
Topics: Adult; Anesthetics, Dissociative; Anorexia; Chronic Disease; Compulsive Personality Disorder; Drug A | 1998 |
Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chronic Disease; Cross-Over Studies; Double-Bl | 1999 |
Clinical experience with oral ketamine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Chronic Disease; Female; Humans; K | 1999 |
Interindividual differences in the analgesic response to ketamine in chronic orofacial pain.
Topics: Adjuvants, Anesthesia; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics | 2001 |
76 other studies available for ketamine and Chronic Disease
| Article | Year |
|---|---|
Ketamine for chronic depression: two cautionary tales
Topics: Adult; Chronic Disease; Depressive Disorder, Treatment-Resistant; Duration of Therapy; Excitatory Am | 2019 |
GRIN2B Gene Polymorphism in Chronic Ketamine Users.
Topics: Adult; Case-Control Studies; Chronic Disease; Gene Frequency; Genetic Markers; Genotype; Humans; Ill | 2020 |
Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus.
Topics: Animals; Chronic Disease; Excitatory Amino Acid Antagonists; Hippocampus; Ketamine; Male; Rats; Rats | 2021 |
Cognitive impairment in chronic ketamine abusers.
Topics: Adult; Anesthetics, Dissociative; Chronic Disease; Cognitive Dysfunction; Executive Function; Female | 2020 |
Ketamine-Magnesium for Refractory Chronic Cluster Headache: A Case Series.
Topics: Adult; Analgesics; Chronic Disease; Cluster Headache; Drug Therapy, Combination; Female; Humans; Inf | 2020 |
Long-term safety and efficacy of sublingual ketamine troches/lozenges in chronic non-malignant pain management.
Topics: Analgesics; Analgesics, Opioid; Chronic Disease; Chronic Pain; Humans; Ketamine; Pain Management; Qu | 2022 |
Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis.
Topics: Adult; Analgesics; Chronic Disease; Female; Humans; Ketamine; Lidocaine; Male; Middle Aged; Migraine | 2021 |
Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability.
Topics: Aged; Amines; Amitriptyline; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Therapy, | 2017 |
Sex-Dependent Effects of Stress on Immobility Behavior and VTA Dopamine Neuron Activity: Modulation by Ketamine.
Topics: Action Potentials; Acute Disease; Animals; Antidepressive Agents; Chronic Disease; Disease Models, A | 2017 |
Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia.
Topics: Animals; Brain; Chronic Disease; Disease Models, Animal; Exploratory Behavior; Ketamine; Male; Memor | 2017 |
Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.
Topics: Aminoacetonitrile; Animals; Antidepressive Agents; Brain; Chronic Disease; Depressive Disorder; Dise | 2018 |
Clinical pattern and prevalence of upper gastrointestinal toxicity in patients abusing ketamine.
Topics: Abdominal Pain; Administration, Inhalation; Adolescent; Adult; Analgesics; Anemia; Case-Control Stud | 2017 |
Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.
Topics: Advisory Committees; Anesthetics, Dissociative; Chronic Disease; Humans; Ketamine; Mood Disorders; O | 2017 |
Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antioxidants; Brain; Chronic Disease; Depressive Diso | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Topical amitriptyline combined with topical ketamine for the management of recalcitrant localized pruritus: a retrospective pilot study.
Topics: Administration, Topical; Adult; Aged; Amitriptyline; Chronic Disease; Female; Follow-Up Studies; Hum | 2013 |
Prepubertal chronic stress and ketamine administration to rats as a neurodevelopmental model of schizophrenia symptomatology.
Topics: Age Factors; Animals; Attention; Behavior, Animal; Central Nervous System; Chronic Disease; Disease | 2013 |
Abnormalities in white matter microstructure associated with chronic ketamine use.
Topics: Adult; Brain Chemistry; Chronic Disease; Diffusion Tensor Imaging; Female; Humans; Ketamine; Male; M | 2014 |
Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
Topics: Administration, Oral; Adult; Anesthetics, Dissociative; Antidepressive Agents; Chronic Disease; Depr | 2014 |
Chronic hematuria and abdominal pain.
Topics: Abdominal Pain; Adolescent; Chronic Disease; Common Bile Duct; Cystitis; Dilatation, Pathologic; Fem | 2014 |
N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia.
Topics: Adult; Chronic Disease; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Male; Neural Pa | 2015 |
Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and "depressed" mice exposed to chronic mild stress.
Topics: Animals; Antidepressive Agents; Aspartic Acid; Chronic Disease; Depressive Disorder; Disease Models, | 2015 |
Low-Dose Ketamine in Chronic Critical Illness.
Topics: Analgesics; Anxiety; Chronic Disease; Critical Care; Critical Illness; Dose-Response Relationship, D | 2016 |
Potential economic impact on hospitalisations of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial.
Topics: Analgesics; Chronic Disease; Cost Savings; Hospitalization; Humans; Ketamine; Neoplasms; Pain Manage | 2016 |
Preventive Treatment with Ketamine Attenuates the Ischaemia-Reperfusion Response in a Chronic Postischaemia Pain Model.
Topics: Analgesics; Animals; Behavior, Animal; Chronic Disease; Complex Regional Pain Syndromes; Disease Mod | 2015 |
Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Chronic Disease; Drugs, Chinese Herbal; Extracellu | 2015 |
Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice.
Topics: Acute Disease; Analgesics; Animals; Chronic Disease; Complex Regional Pain Syndromes; Disease Models | 2015 |
Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.
Topics: Animals; Antidepressive Agents; Apoptosis; Astrocytes; Behavior, Animal; Brain-Derived Neurotrophic | 2016 |
High-Speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Central Ner | 2015 |
Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Behavior, Animal; Chronic Disease; Ketami | 2016 |
Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model.
Topics: Analgesics; Animals; Annexin A2; Antidepressive Agents; Chronic Disease; Depression; Disease Models, | 2016 |
Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.
Topics: Adult; Chronic Disease; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; K | 2016 |
Effects of norketamine enantiomers in rodent models of persistent pain.
Topics: Animals; Behavior, Animal; Chronic Disease; Constriction, Pathologic; Dose-Response Relationship, Dr | 2008 |
An intravenous ketamine test as a predictive response tool in opioid-exposed patients with persistent pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Dissociative; Chronic Disease; Fema | 2009 |
[Ketamine for prevention of postoperative pain: what are the doses and indications?].
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Chronic Disease; Dose-Response Relationship, Drug; | 2009 |
An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients.
Topics: Acute Disease; Adult; Analgesics; Analysis of Variance; Chronic Disease; Dose-Response Relationship, | 2010 |
Ketamine and chronic pain--going the distance.
Topics: Anesthetics, Dissociative; Chronic Disease; Humans; Ketamine; Pain | 2009 |
Cystitis associated with chronic ketamine abuse.
Topics: Chronic Disease; Cystitis; Female; Humans; Ketamine; Male; Substance-Related Disorders | 2009 |
Spinally applied ketamine or morphine attenuate peripheral inflammation and hyperalgesia in acute and chronic phases of experimental arthritis.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Animals; Arthritis, Experimental; Chronic Disease; Fe | 2010 |
Synthesis and determination of acute and chronic pain activities of 1-[1-(3-methylphenyl) (tetralyl)]piperidine as a new derivative of phencyclidine via tail immersion and formalin tests.
Topics: Acute Disease; Analgesics; Anesthetics, Dissociative; Animals; Chronic Disease; Female; Formaldehyde | 2010 |
What is considered long-term pain relief in chronic pain management? Re: Sigtermans et al., Pain 2009;145:304-311.
Topics: Analgesics; Chronic Disease; Complex Regional Pain Syndromes; Cost-Benefit Analysis; Drug Administra | 2010 |
When managing established osteonecrosis of the jaw, don't forget the not-infrequent chronic refractory pain.
Topics: Chronic Disease; Disease Management; Female; Humans; Jaw Diseases; Ketamine; Middle Aged; Morphine; | 2010 |
Ketamine for managing perioperative pain in opioid-dependent patients with chronic pain: a unique indication?
Topics: Chronic Disease; Disease Management; Humans; Ketamine; Opioid-Related Disorders; Pain; Pain, Postope | 2010 |
Research suggests new drug targets for depression. Pilot studies of ketamine intrigue scientists, but risks of this anesthetic limit its clinical use.
Topics: Anesthetics, Dissociative; Bipolar Disorder; Brain; Chronic Disease; Depressive Disorder, Major; Dou | 2010 |
Intraoperative ketamine and chronic opioid use: less pain, more morphine?
Topics: Analgesics; Analgesics, Opioid; Chronic Disease; Follow-Up Studies; Humans; Intraoperative Care; Ket | 2011 |
Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain.
Topics: Acute Disease; Analgesics; Animals; Chronic Disease; Cold Temperature; Data Interpretation, Statisti | 2011 |
Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys.
Topics: Adolescent; Analysis of Variance; Animals; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; | 2014 |
Repeated peripheral nerve blocks by the co-administration of ketamine, morphine, and bupivacaine attenuate trigeminal neuralgia.
Topics: Analgesics, Opioid; Anesthesia, Local; Anesthetics, Dissociative; Bupivacaine; Chronic Disease; Huma | 2003 |
Effect of long-term ketamine administration on vocalization to paw pressure and on spinal wind-up activity in monoarthritic rats.
Topics: Analgesics; Analysis of Variance; Animals; Arthritis, Experimental; Arthritis, Infectious; Chronic D | 2003 |
Ketamine in the management of chronic pancreatic pain.
Topics: Aged; Analgesics; Chronic Disease; Humans; Ketamine; Male; Pain; Pancreatitis | 2003 |
Ketamine attenuates hypocapnia-induced neuronal damage in the caudoputamen in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Cerebrovascular Circulation; Chronic Disease; Dementia, Vascular; Excitatory Amino Acid Ant | 2004 |
Safety and efficacy of intranasal ketamine in a mixed population with chronic pain.
Topics: Administration, Intranasal; Chronic Disease; Clinical Trials as Topic; Humans; Ketamine; Pain | 2004 |
Comment on: Bell RF, Kalso K. Is intranasal ketamine an appropriate treatment for chronic non-cancer breakthrough pain? Pain 2004;108:1-2.
Topics: Administration, Intranasal; Chronic Disease; Humans; Ketamine; Pain | 2004 |
Are preemptive analgesic effects of ketamine linked to inadequate perioperative analgesia?
Topics: Analgesia; Anesthetics, Dissociative; Chronic Disease; Female; Gynecologic Surgical Procedures; Huma | 2004 |
Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic pain.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Anti-Inflammatory Age | 2005 |
A fatal chronic ketamine poisoning.
Topics: Adult; Anesthetics, Dissociative; Autopsy; Chronic Disease; Female; Fibrosis; Homicide; Humans; Keta | 2005 |
Club drug use among young men who have sex with men in NYC: a preliminary epidemiological profile.
Topics: Adolescent; Adult; Anesthetics, Dissociative; Central Nervous System Stimulants; Chronic Disease; Cr | 2005 |
[Postponed or canceled drug challenge tests and side effects of the test drug--a report of four cases].
Topics: Adult; Aged; Arthritis, Rheumatoid; Chronic Disease; Female; Fibromyalgia; Humans; Intervertebral Di | 2006 |
High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients.
Topics: Adult; Blinking; Chronic Disease; Electromyography; Female; Glutamic Acid; Glycine; Humans; Inhibiti | 2007 |
Determination of sensitivity of male Wistar rats to an equal dose of ketamine/xylazine injection at anesthetic dose in a chronic model of hypernatremia in comparison with control group.
Topics: Adrenergic alpha-Agonists; Anesthesia; Anesthetics, Dissociative; Animals; Chronic Disease; Disease | 2007 |
Ketamine blocks enhancement of spinal long-term potentiation in chronic opioid treated rats.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Animals; Chronic Disease; Drug Synergism; Electric St | 2008 |
Anorectal manometry under anesthesia in the investigation of children with chronic constipation.
Topics: Anesthesia; Biopsy; Child; Child, Preschool; Chronic Disease; Constipation; Halothane; Humans; Infan | 1982 |
Pemphigus vulgaris: anaesthesia in the traumatised patient.
Topics: Adult; Anesthesia, General; Anesthesia, Intravenous; Chronic Disease; Diazepam; Female; Humans; Keta | 1982 |
Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Facial Pain; Female; Follow-Up Studies; Humans; Inciden | 1995 |
Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization.
Topics: Adolescent; Appendectomy; Brain; Chronic Disease; Female; Humans; Ketamine; Pain, Postoperative; Reo | 1995 |
The involvement of N-methyl-D-aspartate (NMDA) and non-NMDA receptors in the responsiveness of rat spinal neurons with input from the chronically inflamed ankle.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Animals; Ankle | 1994 |
Long-term treatment of chronic neuropathic pain with the NMDA (N-methyl-D-aspartate) receptor antagonist ketamine.
Topics: Central Nervous System; Chronic Disease; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pain | 1997 |
Ketamine: relief from chronic pain through actions at the NMDA receptor?
Topics: Anesthetics, Dissociative; Chronic Disease; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pai | 1996 |
Reply to S.T. Meller: Ketamine: relief from chronic pain through actions at the NMDA receptor.
Topics: Chronic Disease; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pain; Receptors, N-Methyl-D-As | 1997 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |
Subpial vacuolar myelopathy after intrathecal ketamine: report of a case.
Topics: Anesthetics, Intravenous; Carcinoid Tumor; Chronic Disease; Fatal Outcome; Humans; Injections, Spina | 1997 |
Ketamine analgesia, NMDA receptors and the gates of perception.
Topics: Analgesics; Arteriosclerosis; Chronic Disease; Excitatory Amino Acid Antagonists; Humans; Ion Channe | 1998 |
Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report.
Topics: Administration, Oral; Adult; Analgesics; Chronic Disease; Humans; Ketamine; Male; Neuralgia; Spinal | 1999 |
An unusual case of chronic neuropathic pain responds to an optimum frequency of intravenous ketamine infusions.
Topics: Adult; Chronic Disease; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Pain; Phantom L | 2001 |
Experimental conditions for the continuous subcutaneous infusion of four central analgesics in rats.
Topics: Acetates; Amines; Analgesics; Anesthetics, Dissociative; Animals; Anticonvulsants; Antidepressive Ag | 2002 |
[Effect of ketamine anesthesia and stress due to bronchoscopy on immunity indices of cancer and noncancer patients].
Topics: Adult; Aged; Anesthesia; Antibody Formation; B-Lymphocytes; Bronchoscopy; Chronic Disease; Female; H | 1986 |